Results: Both groups showed comparable significant (p < 0.001) within-group improvement from baseline to endpoint (LOCF) in Positive and Negative Symptoms Scale (PANSS) total and subscale scores. Of the olanzapine-treated children, 11 (91.7%) completed the 12 weeks of the study, whereas in the risperidone-treated children only 9 (69.2%) did. No significant differences between risperidone-treated children and olanzapine-treated children were observed on Barnes Akathisia Rating Scale (BAS) and Simpson-Angus Scale (SAS) rating scales. Both treatment groups showed significant (p < 0.001) increase in weight from baseline to endpoint.
INTRODUCTION C
HILDHOOD-ONSET SCHIZOPHRENIA (COS), defined as onset of psychosis before the age of 12 years, is a rare, clinically severe form of schizophrenia. COS is associated with disrupted cognitive, linguistic, and social development well before the appearance of frank psychotic symptoms . Children and adolescents who develop 394 MOZES ET AL. schizophrenia as adults have higher rates of abnormal speech and motor development, poorer social development, lower intelligence, and worse educational performance. Premorbid language impairment may be an early manifestation of the neurodevelopmental abnormalities underlying schizophrenia (Davidson et al. 1999; Nicolson et al. 2000) . COS children spend months and even years in psychiatric wards, time that is extremely important to their normal development. Delayed identification of COS and inappropriate intervention lead to increased morbidity and decrease the potential of optimal response (DeQuardo 1998). Early intervention has a significant impact on outcome and may attenuate the deterioration and chronicity of the illness (DeQuardo 1998). For these reasons it is important to start antipsychotic treatment as early as possible.
In the preatypical antipsychotic era, haloperidol and other typical antipsychotics were used for treating COS. The first atypical antipsychotic that was used for treating children was clozapine. The clozapine-treated patients showed a significant improvement in both positive and negative symptoms compared to haloperidol in a 6-week doubleblind study of treatment-refractory children and adolescents with schizophrenia (Kumra et al. 1996) . The atypical antipsychotics have also decreased rates of extrapyramidal symptoms (EPS) and have some positive effect on cognition (Toren et al. 2004) . One of the factors that significantly decreases compliance is the 18-week white blood count (WBC) followup necessary with clozapine treatment (Toren et al. 2004 ). The introduction of newer atypical antipsychotics such as risperidone and olanzapine has opened a new era in the treatment of COS.
Risperidone is a benzisoxazole derivative with high affinity for the serotonin (5-hydroxytryptamine 2A; 5-HT2A) and dopamine D2 receptors, and a 5-HT2A/D2 affinity ratio of 8:1. Risperidone also binds with a moderate to high affinity to the ␣1-and ␣2-adrenoceptors and D1, D3, and D4 receptors, and histamine H1 receptors. Unfortunately, to the best of our knowledge, there are very little data on the efficacy of atypical antipsychotics in children diagnosed with COS. Clinical trials with risperidone demonstrated significant improvement in children and adolescent patients. Two trials have shown improvement in both positive and negative symptoms (Gothelf et al. 2003; Zalsman et al. 2003) , and another trial has shown improvement only in positive symptoms (Grcevich et al. 1996) . The major side effects that were reported in children treated with risperidone are extrapyramidal side effects, somnolence, weight gain, depression, and symptoms associated with hyperprolactinemia, which can lead to hypogonadism-induced osteoporosis, galactorrhea, gynecomastia, irregular menstruation, and sexual dysfunction. In addition, elevations of liver enzymes and orthostatic hypotension, hyperlipidemia, and hyperglycemia were noticed in some studies (Toren et al. 2004) .
Olanzapine is a thienobenzodiazepine derivative with moderate to high affinity for the 5-HT2A, 5-HT2C, muscarinic M1, H1, ␣-1, D1, D2, and D4 receptors. Olanzapine, like other atypical antipsychotics, may be more beneficial than typical antipsychotics for both the negative and positive symptoms of schizophrenia (Bhana et al. 2001) , even in treating chronic drug-resistant COS (Kumra et al. 1998; Mozes et al. 2003) . In a 1-year open-label trial of olanzapine in school-aged children diagnosed with schizophrenia, a significant improvement in positive symptoms was obtained in the early stages of the study after 6 weeks, while the improvement in negative symptoms and anxiety was achieved after 1 year of treatment (Ross et al. 2003) .
The main adverse side effects reported in children treated with olanzapine are increased appetite and weight gain, which may be attributable to the high-5-HT2C and histamine H1 antagonism (Remschmidt et al. 2000) . Sedation is one of the most significant adverse side effects of olanzapine treatment in this age group (Sholevar et al. 2000) . Other adverse side effects include gastrointestinal symptoms, headaches, insomnia, difficulties concentrating, liver function abnormalities, sustained tachycardia, and agitation (Toren et al. 2004) .
In adult patients with schizophrenia, there are two large comparative studies of olanzapine versus risperidone. In a 28-week, multicenter, double-blind prospective study conducted with 339 patients who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (American Psychiatric Association 1994) criteria for schizophrenia, schizoaffective, or schizophreniform disorder, Tran et al. (1997) found an apparently equal efficacy of both drugs in the management of psychotic symptoms and a greater efficacy of olanzapine in alleviating negative symptoms. The occurrence of extrapyramidal side effects, hyperprolactinemia, and sexual dysfunction were statistically lower in olanzapine-treated patients (Tran et al. 1997) . In a similar study, both drug treatments were well tolerated and efficacious, but a greater reduction in the severity of positive and affective symptoms was seen with the risperidone treatment. The frequency and severity of extrapyramidal symptoms were the same in the two treatment groups, but a greater weight gain was associated with the olanzapine treatment (Conley and Mahmoud 2001) .
Unfortunately, there are only few prospective and retrospective open clinical trials of risperidone and olanzapine in COS. There is an extreme paucity of data comparing the effectiveness and tolerability of risperidone with olanzapine or either of these drugs with typical antipsychotics in this unique population. To our knowledge, there is only one open clinical trial that has compared three of the most commonly used antipsychotic medications-risperidone, olanzapine, and haloperidol-in the treatment of adolescents with schizophrenia (Gothelf et al. 2003) . In this study, significant clinical improvement in both positive and negative symptoms was found for all medications. Olanzapine and haloperidol induced fatigability more frequently than risperidone, and haloperidol was associated with a higher frequency of depression and more severe extrapyramidal symptoms. The small sample size and lack of randomization were the major limitations of this study. There is an unmet need for such comparative studies in COS.
In the present open-label, randomized, prospective study, we compared the effectiveness and tolerability of risperidone versus olanzapine in the treatment of COS inpatients.
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The study was a comparative, randomized, prospective, flexible-dose, open-label trial conducted at the Department of Child Psychiatry in the Ness Ziona Mental Health Center in Israel. The Ness Ziona Mental Health Center Institutional Review Board approved the study and written informed consent was obtained from the parents of all patients after full explanation of the nature of the study.
Subjects
Twenty-five hospitalized children, 10 boys and 15 girls, 9-14 years old (mean age 11.09 ± 1.55 years) participated in the study. Participants were COS children who were hospitalized at the Department of Child Psychiatry at the Ness Ziona Mental Health Center, (Ness Ziona Israel). Diagnosis was based on a semistructured interview Kiddies Schedule for Affective Disorders and Schizophrenia (K-SADS) (Apter et al. 1989 ), conducted by two child and adolescent psychiatrists and according to the DSM-IV criteria. The clinical data of the study population are described in Table 1 . Ten patients were diagnosed with schizophreniform disorder (subjects 2, 3, 6, 8, 9, 11, 13, 14, 24, 25) 7 were diagnosed with disorganized schizophrenia (subjects 4, 10, 16, 17, 18, 19, 21) , 6 were diagnosed with paranoid schizophrenia (subjects 1, 5, 7, 15, 20, 23) , and 2 patients were diagnosed with unspecified schizophrenia (subjects 12, 22). Three children suffered also from obsessive compulsive disorder (OCD) (subjects 2, 11, 18), 3 from attention-deficit/hyperactivity disorder (ADHD) (subjects 6, 14, 20), 2 from grand mal epilepsy (subjects 2, 10), 1 from neurofibromatosis (subject 12), 1 from Familial Mediterranean Fever (subject 9), and 1 from chronic motor tic disorder (subject 13). Children were excluded from the study if they had mental retardation. The participants were randomly assigned to either of the medication groups (olanzapine or risperidone). The dose of each drug was determined according to the clinical response. Five boys and 8 girls 8.75-13.25 years old (mean age 10.71 ± 1.43 years) were assigned to the risperidone group, and 5 boys and 7 girls 8.5-14 years old (mean age 11.5 ± 1.64 years) to the olanzapine group. This study was an add-on; prior nonantipsychotic drug treatment was continued for 2-12 weeks. Biperiden was added according to clinical judgment (Table 1) .
Study design
After an evaluation, the inpatients received risperidone (0.25-4.5 mg/day, mean dose 1.62 ± 1.02 mg/day) or olanzapine (2.5-20 mg/day, mean dose 8.18 ± 4.41 mg/day) for 12 weeks, with weekly evaluations on the following scales: Positive and Negative Syndrome Scale (PANSS) (Kay et al. 1987 ), The Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham 1962) , Simpson-Angus Scale (SAS) (Simpson and Angus 1970) , Barnes Akathisia Rating Scale (BAS) (Barnes 1980) , and the Childrens Global Assessment Scale (CGAS) (Shaffer et al. 1983 ). In addition, weight, pulse and blood pressure were monitored once weekly. The initial dose of risperidone was 0.25 mg/day and of olanzapine 2.5 mg/day; dose was adjusted according to the clinical response and side effects. There were no fixed time points for alterations in the dosage.
Patients were assigned to a treatment group by randomized allocation. The children and their treating psychiatrist were not blind to the medication assignment. All inpatients, except one, did not have prior exposure to neuroleptics. This one patient had been treated previously with risperidone.
Statistical analysis
Analysis was conducted on an intent-to-treat basis. The baseline measure was the week 0 observation. The endpoint measure was the last measure observed during the 12 weeks of the trial (last observation carried forward [LOCF] ). Comparison between the two treatment groups and along the study period was performed using analysis of variance with repeated measures (ANOVA-RM). Two-tailed, paired t test, Pearson's Chi-square, Pearson's correlation test, and Bonferroni correction were performed as appropriate. All results are expressed as mean ± SD. Significance was determined at under 0.05 level.
RESULTS
A total of 25 patients were included in this study: olanzapine (n = 12), risperidone (n = 13). The two groups were comparable in all baseline demographic data and severity of illness. There was no significant gender distribution difference between the two medication groups (Table 2) .
Effectiveness
The primary effectiveness outcome measure was the total PANSS. The tolerability outcome measure was the dropout rate. The secondary outcome measures were the PANSS subscale scores, BPRS scores, SAS scores, BAS scores, and CGAS scores. Both the olanzapine and risperidone treatment groups showed significant (p < 0.001) within-group improvement from baseline to endpoint (LOCF) in all PANSS scores. Analysis of change in PANSS subscale scores by week showed similar change in both groups over the 12 week of the study (Fig. 1 ).
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There were no significant between-group differences in the improvement in all PANSS measurements and CGAS (Table 3) .
There was no difference in the percentage of children achieving at least 30% reduction in all PANSS subscales. There was a trend toward a
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A. PANSS total score by week significant difference in the percentage of children achieving greater than 50% reduction in negative PANSS scores (olanzapine 41.7% vs. risperidone 7.7%, p = 0.047); however, this difference did not remain significant following Benferroni correction (Table 4) .
Dropout rate
There was a difference between the two treatment groups in completion rate at week 12. Of the olanzapine-treated children, 11 (91.7%) completed the 12 weeks of the study, whereas in the risperidone-treated children only 9 (69.2%) completed the 12 weeks of the study; however, this difference did not reach a significant level (Pearson's Chi-square test, p = 0.161). The one olanzapine-treated patient who did not complete the 12 weeks of the study (subject 8) was released from the hospital at week 7 because no further hospitalization was required; she continued treatment with olanzapine on an ambulatory basis, and contact with her was lost.
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Of the 4 risperidone participants who did not complete the 12 weeks of the study, 3 dropped out due to lack of improvement (subject 2, 2.5 mg/day, week 7; subject 10, 3 mg/day, week 9; subject 19, 4 mg/day, week 5), and 1 due to severe hyperprolactinemia and reduction of growth hormone level (subject 25, stopped risperidone treatment at week 10, prolactin level at week 6 = 55.8 µg/L; growth hormone level at week 6 = 0.07 µg/L).
SAFETY

Adverse side effects
Treatment-emergent adverse events were monitored by the BAS and SAS rating scales. No significant differences between risperidone-treated children and olanzapine-treated children were observed in the rate of children who developed extrapyramidal side effects as assessed by BAS and SAS rating scales (Table  5) . Seven olanzapine-treated children and 8 risperidone-treated children exhibited extrapyramidal adverse effects. Three olanzapinetreated children and one risperidone-treated child developed akathisia (Tables 5 and 6 ). There was a difference in some adverse side effects reported on these questionnaires (Table 6) .
Weight
Weight measurements were available for 11 participants of the olanzapine-treated group and 9 of the risperidone-treated group (partici-400 MOZES ET AL. pants who completed 12 weeks of the study). Both treatment groups showed significant (p < 0.001) increase in weight from baseline to endpoint. The mean weight gain was 5.78 ± 3.11 kg for the olanzapine-treated group and 4.45 ± 2.87 kg for the risperidone-treated group. There was no significant difference in weight gain between the two treatment groups (t 18 = 0.99, p = 0.33).
Blood pressure and pulse
There were no statistically significant differences between the two groups in blood pressure and pulse.
DISCUSSION
This open-label randomized study compared the clinical effectiveness of risperidone versus olanzapine treatment in children with schizophrenia. It appears that both treatments have beneficial effects and are relatively well tolerated. The doses of olanzapine and risperidone in our child population were similar to the doses used in adult schizophrenia patients (the mean dose for olanzapine was 8.18 ± 4.41 mg/day and for risperidone 1.62 ± 1.02 mg/day).
Both the olanzapine and risperidone treatment groups showed significant within-group improvement from baseline to endpoint in both positive and negative scores. Such a beneficial effect has been reported previously in adolescent and child patients treated with atypical antipsychotic drugs (Armenteros et al. 1997) . This comparable improvement indicates the effectiveness of both medications in childhood-onset psychosis. There were no significant between-group differences in the magnitude of impact in all PANSS and CGAS measurements. However, there was a trend (nonsignificant following Benferroni correction) toward superiority of olanzapine as measured in the percentage of children achieving greater than 50% reduction in negative PANSS scores as well as a numerical advantage of olanzapine in all PANSS subscale scores (Table  3) . Given the small sample sizes, it is likely that we did not have sufficient power to detect any difference between the groups due to possible type II error. Zalsman et al. (2003) reported a relatively weak effect of risperidone on negative schizophrenia symptoms in an adolescent population (Zalsman et al. 2003) . Our clinical observation, in addition to previous data about the efficacy of olanzapine in some children and adolescents with treatmentrefractory schizophrenia, may be relevant to the choice of medication in treating COS (Kumra et al. 1998; Mozes et al. 2003) .
Not all participants completed the 12 weeks of the study. Four of the risperidone group discontinued treatment, 3 due to lack of improvement and 1 due to a clinically significant elevated prolactin level. In contrast, only one of the olanzapine-treated children did not continue the 12 follow-up weeks of the study. She was discharged from the hospital due to significant improvement and contact with her was lost. The observation that more olanzapine-treated patients completed the treatment protocol (91.7% vs. 69.2%) may suggest some advantage of olanzapine in this respect. The main cause of dropouts in risperidone-treated group was lack of improvement. This finding is in accordance with another study in adults that found that more olanzapine-treated patients completed a 30-week period compared with risperidone-treated patients (Gureje et al. 2003) . However given the relatively low risperidone dose (mean dose 1.62 ± 1.02 mg/ day), it is still possible that this difference is related to underdosing of risperidone.
Treatment-emergent extrapyramidal adverse events as detected by the BAS and SAS rating scales indicated that the number of events was relatively small, with no significant differences between the two treatment groups. Olanzapine is usually associated with lower rate of EPS compared with risperidone (Grcevich et al. 1996; Gothelf et al. 2003; Zalsman et al. 2003) . Our findings of no difference may be related to the small sample size and the relatively low dose of risperidone (mean dose 1.62 ± 1.02 mg/day).
Weight gain was very common in both groups, with no significant difference between the two treatment groups. In contrast to our findings, previous studies have shown a larger weight gain in olanzapine-treated adolescents as compared with risperidone (Ratzoni et al. 2002) . It is possible that in COS children, in contrast to adolescents and adults, there is no difference between the two agents in weight gain.
The major limitations of the study were the open-label design of the study, the small sample size, and the relatively short follow-up period (12 weeks). The open-label nature of the study reduced the significance of the findings by introducing obvious biases. In addition, many patients in both groups (8/25) were co-treated with either mood stabilizers or selective serotonin reuptake inhibitors (SSRIs) ( Table 1 ). These agents have effects on aggression (Rana et al. 2005 ), anxiety and depression (Hamrin and Scahill 2005), or negative symptoms (Silver 2004 ) , as well as on side effects such as weight gain (Bowden 2005) and akathisia (Lane 1998).
CONCLUSION
Both olanzapine and risperidone are efficacious and relatively safe in the treatment of COS, with a slight statistically nonsignificant advantage of olanzapine in the dimensions of negative symptoms and dropout rate. Largescale, randomized, double-blind, placebocontrolled comparative studies with longer follow-up periods are needed to evaluate further the effectiveness of these antipsychotics in COS.
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